Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.
نویسندگان
چکیده
BACKGROUND While standards for the treatment of newly diagnosed glioblastomas exist, therapeutic regimens for tumor recurrence remain mostly individualized. The role of a surgical resection of recurrent glioblastomas remains largely unclear at present. This study aimed to assess the effect of repeated resection of recurrent glioblastomas on patient survival. METHODS In a multicenter retrospective-design study, patients with primary glioblastomas undergoing repeat resections for recurrent tumors were evaluated for factors affecting survival. Age, Karnofsky performance status (KPS), extent of resection (EOR), tumor location, and complications were assessed. RESULTS Five hundred and three patients (initially diagnosed between 2006 and 2010) undergoing resections for recurrent glioblastoma at 20 institutions were included in the study. The patients' median overall survival after initial diagnosis was 25.0 months and 11.9 months after first re-resection. The following parameters were found to influence survival significantly after first re-resection: preoperative and postoperative KPS, EOR of first re-resection, and chemotherapy after first re-resection. The rate of permanent new deficits after first re-resection was 8%. CONCLUSION The present study supports the view that surgical resections of recurrent glioblastomas may help to prolong patient survival at an acceptable complication rate.
منابع مشابه
Re-do Craniotomy for Recurrent Grade IV Glioblastomas: Impact and Outcomes from the National Neuroscience Institute Singapore.
AIM We hypothesize that re-do craniotomy for recurrent grade IV glioblastomas improves survival while preserving outcome in selected patients. METHODS A retrospective analysis was conducted of 141 patients, from a prospectively collected database from 2004-2014, with grade IV glioblastomas who underwent craniotomy and excision. Sixty-five patients were included in our analysis. Twenty patient...
متن کاملبررسی موارد و عوامل مؤثر در عود مننژیوم مغزی طی یک دوره 20 ساله
Background: Meningiomas are common benign tumors of the brain. Meningioma patients have optimal functional recovery after surgical removal of their tumors. Some patients experience recurrence months or years after surgical resection. In this study, we try to determine the prevalence of recurrent meningioma and the correlation between recurrence and certain factors. Methods: This retrospective ...
متن کاملLoss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
PURPOSE Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide. Recently, inactivating mutations in the mismatch repair gene MSH6 were identified in two glioblastomas recurrent post-temozolomide. Because mismatch repair pathway inactivation is a known mediator of alkylator resistance in vitro, these f...
متن کاملMechanisms of evasion to antiangiogenic therapy in glioblastoma.
Recognition of the role of vascular endothelial growth factor (VEGF) in developing the rich vascularity of glioblastomas, which contributes to their growth and resistance to radiation, surgery, and chemotherapy, has led to clinical trials of agents targeting VEGF or VEGF receptors 1 and 2. VEGF has been targeted with the mouse anti-human VEGF antibody avastin (bevacizumab), which has undergone ...
متن کاملMSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Glioblastomas are the most commonly diagnosed primary human brain tumors. Unfortunately, these cancers are almost uniformly fatal; regardless of treatment, median survival is less than 2 years after diagnosis.20 Current standard of care is maximal safe surgical resection followed by combined adjuvant radiation therapy and chemotherapy with the methylating alkylator agent temozolomide. Nonethele...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Neuro-oncology
دوره 18 1 شماره
صفحات -
تاریخ انتشار 2016